BFS
FATE icon

Bradley Foster & Sargent’s Fate Therapeutics FATE Stock Holding History

Bradley Foster & Sargent’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-4,657
Closed -$276K – 457
2021
Q3 		$276K Hold
4,657
– – 0.01% 370
2021
Q2 		$404K Sell
4,657
-3,734
-45% -$301K 0.01% 328
2021
Q1 		$692K Sell
8,391
-17
-0.2% -$1.63K 0.02% 260
2020
Q4 		$765K Sell
8,408
-612
-7% -$38K 0.02% 248
2020
Q3 		$361K Buy
+9,020
New +$315K 0.01% 282

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bradley Foster & Sargent's FATE Position: Q4 2021 in Review

Bradley Foster & Sargent sold out of Fate Therapeutics (FATE) in Q4 2021, closing a stake of 4,657 shares — an estimated $276K sold.

Bradley Foster & Sargent first reported a position in FATE in Q3 2020 and held it in 5 quarters. The position peaked at $765K in Q4 2020. 250 funds tracked by Wall St. Rank hold FATE as of Q4 2021.

  • Bradley Foster & Sargent reported no remaining Fate Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Bradley Foster & Sargent sold 4,657 Fate Therapeutics shares in Q4 2021, an estimated $276K.
  • Bradley Foster & Sargent first reported a position in Fate Therapeutics in Q3 2020 and held it in 5 quarters.
  • Bradley Foster & Sargent's Fate Therapeutics position peaked at $765K in Q4 2020.
  • 250 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2021.

Based on Bradley Foster & Sargent's 13F filing for Q4 2021, filed 11 Mar 2022.